阅读说明：本技术 δ样配体1用于诊断严重感染 (Ligand 1 for diagnosing severe infection ) 是由 达格玛·希尔德勃兰特 克劳斯·黑格 弗洛里安·乌勒 马库斯·韦根 于 2018-10-25 设计创作，主要内容包括：本发明涉及一种用于体外诊断严重感染的方法,该方法包括确定生物样品中的δ样配体1蛋白或编码δ样配体1蛋白的核苷酸序列,其中δ样配体1蛋白的表达水平升高或编码δ样配体1蛋白的核苷酸序列的水平升高则表明严重感染；本发明还涉及δ样配体1蛋白作为用于体外诊断严重感染(如脓毒症)的生物标志物的应用。(The present invention relates to a method for in vitro diagnosis of a severe infection, the method comprising determining in a biological sample a ligand-1-like protein or a nucleotide sequence encoding a ligand-1-like protein, wherein an elevated level of expression of ligand-1-like protein or an elevated level of the nucleotide sequence encoding ligand-1-like protein is indicative of a severe infection; the invention also relates to the use of the ligand 1-like protein as a biomarker for the in vitro diagnosis of severe infections (such as sepsis).)

1. Use of a ligand-like 1 protein or a nucleotide sequence encoding a ligand-like 1 protein as a biomarker for diagnosing severe infection in vitro.

2. Use according to claim 1, wherein said ligand 1-like protein is encoded by the nucleotide sequence SEQ ID NO 1.

3. Use according to claim 1 or 2, wherein said ligand 1-like protein is a protein having at least 90% identity with the amino acid sequences SEQ ID No. 2 and SEQ ID No. 3.

4. Use according to claims 1 to 3, wherein the like ligand 1 protein is a cleavage product of the like ligand 1 protein, in particular wherein the cleavage product is a protein having the amino acid sequence SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6 and/or SEQ ID NO 7.

5. Use according to any one of the preceding claims, wherein an elevated level of expression of a like ligand 1 protein or a nucleotide sequence encoding a like ligand 1 protein is indicative of a diagnosis of infection.

6. The use according to any one of the preceding claims, wherein the severe infection is sepsis.

7. The use of any one of the preceding claims, wherein the expression level is determined in a biological sample.

8. The use of claim 7, wherein the biological sample is selected from the group consisting of whole blood, buffy coat, plasma, serum, Peripheral Blood Mononuclear Cells (PBMCS), neutrophils, monocytes, T cells, urine, spinal fluid, lymph fluid, external skin secretions, tears, and/or saliva.

9. Use according to claim 5, wherein the expression level is determined in a biological sample taken from a patient after surgery, in particular after abdominal surgery.

10. Use according to claims 1 to 9, wherein the use is as a guide for antibiotic therapy.

11. A method for in vitro diagnosis of a severe infection comprising determining in a biological sample a ligand-like 1 protein or a nucleotide sequence encoding a ligand-like 1 protein, wherein an elevated level of expression of the ligand-like 1 protein or an elevated level of the nucleotide sequence encoding the ligand-like 1 protein is indicative of an infection.

12. The method of claim 11, wherein said ligand 1-like protein is encoded by the nucleotide sequence of SEQ ID No. 1 or a nucleotide sequence having at least 80% identity to SEQ ID No. 1.

13. The method of claim 11, wherein said ligand 1-like protein has an amino acid sequence with at least 90% identity to SEQ ID No. 2 or SEQ ID No.3 and/or has the amino acid sequence SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6 and/or SEQ ID No. 7.

14. The method according to any one of claims 11 to 13, wherein the biological sample is selected from the group consisting of whole blood, buffy coat, plasma, serum, Peripheral Blood Mononuclear Cells (PBMCS), neutrophils, monocytes, T cells, urine, spinal fluid, lymph fluid, external skin secretions, tears and/or saliva.

15. The method according to any one of claims 11 to 14, wherein the expression level is determined in a biological sample taken from the patient after surgery, in particular after abdominal surgery.

Technical Field

The present invention relates to the use of ligand-like 1 as a biomarker in the diagnosis of severe infections and to a method for the rapid in vitro diagnosis of severe infections (such as sepsis) by controlling the level of ligand-like 1 in a biological sample.

Background

Biomarkers are measurable characteristics of an organism that reflect a particular physiological state. In medicine, biomarkers are generally compounds isolated from biological tissues that can be used as an indicator of the presence or severity of a particular disease state, or to monitor the effectiveness of the intervention being used.

Biomarkers are particularly useful in the diagnosis and possible prognosis of a disease, as well as in monitoring the progression of a disease or response to treatment. The ideal biomarker should be readily available and measurable, and should be reliable in terms of high sensitivity and specificity for disease.

Severe infections (especially sepsis) are medical conditions that should be avoided in particular, but for which there are no highly reliable biomarkers. Severe infections, including sepsis, are characterized by and/or can cause life-threatening organ failure induced by a deregulated immune response to the infection. In sepsis, the host response elicited by microbial pathogens peaks in the pathological syndrome characterized by excessive inflammation and subsequent immunosuppression.

Despite the steady improvements in intensive care medicine and antimicrobial therapy, this infection remains a leading cause of death in intensive care units of all ages worldwide. To improve outcome and at the same time avoid unnecessary antibiotic treatment, a fast, reliable test for diagnosing severe infections is essential.

Sepsis is a serious life-threatening infection. Blood culture is still the gold standard for the diagnosis of sepsis to date, but blood culture takes time and many patients with signs and symptoms of sepsis have negative blood cultures. Therefore, there is an urgent need for a complementary method for diagnosing severe infections, in particular for diagnosing sepsis.

The document "C.Pierrakos and J. -L. Vincent (2010) clinical Care,14: R15" describes that biomarkers known in the art can be used to identify or rule out sepsis.

The literature "Van Engelen et al, (2018)" Biomarkers in Sepsis ", Critical CareClins, 34(1): 129-.

WO 2016/145426 a1 describes a method of diagnosing sepsis using the expression levels of CEACAM1, ZDHHC19, C9orf95, GNA15, BATF, C3AR1, KIAA1370, TGFBI, MTCH1, RPGRIP1 and H L a-DPB1 as biomarkers.

US 2005/059093 a1 describes a method for detecting a modulator of the Notch signaling pathway comprising the steps of: monitoring a Notch signaling pathway in a cell of the immune system in the presence and absence of the candidate modulator, and determining whether the candidate modulator modulates the Notch signaling pathway.

WO 2017/004159A1 describes compositions that bind to soluble biomolecules and inhibit the biological activity of the soluble biomolecules to inhibit the interaction of a target or pathogen with other molecules or cells, wherein it is mentioned that Notch ligands, including the like ligand 1(D LL 1), are particularly useful for the treatment or prevention of atherosclerosis, calcified aortic stenosis, heart failure, stroke and cancer, for the treatment or prevention of sepsis associated with infection by a pathogen, WO 2017/004159A1 proposes the selective binding of TNF α, interleukin 1, interleukin 6, interleukin 8, interleukin 12, interferon gamma, macrophage migration inhibitory factor, GM-CSF and/or coagulation factors.

US 2006/140943 a1 describes the use of modulators of the Notch signaling pathway for the preparation of a medicament for the treatment of Graft Versus Host Disease (GVHD) and diseases and disorders caused by or associated with transplants, such as transplants of organs, tissues and/or cells (e.g. bone marrow transplants), wherein the modulators are used to reduce the responsiveness of cells of the immune system.

WO 2012/092539 a2 describes antibodies to D LL 4 and methods for treating diseases associated with D LL 4, such as cell proliferative diseases or pathological conditions associated with angiogenesis WO 2012/092539 a2 describes that dysregulation of angiogenesis can lead to neoplastic and non-neoplastic diseases and sepsis is designated as one of many such non-neoplastic diseases.

US 9,731,024B 2 and US 2017/0240590 a1 describe materials and methods for conjugating water soluble polymers to the oxidized carbohydrate moiety of therapeutic proteins. Many proteins are listed as therapeutic proteins, one of which is like protein 1.

Currently, several biomarkers are used to diagnose severe infections, such as sepsis. Pre-calcitonin (PCT) and C-reactive protein (CRP) as well as white blood cell counts have been most widely used in the acute phase.

However, the effectiveness of PCT and CRP is limited by their lack of specificity and sensitivity for sepsis. In particular, it remains difficult to distinguish sepsis from inflammation of other non-infectious causes. Therefore, new sepsis biomarkers with higher reliability are needed.

Disclosure of Invention

The problem underlying the present invention is to provide a biomarker which can be used to diagnose a severe infection with a high level of reliability.

This problem is solved by using the like ligand 1 protein (D LL 1) or a nucleotide sequence encoding the like ligand 1 protein as a biomarker for the in vitro (ex vivo) diagnosis of severe infections, whereby an elevated level of the like ligand 1 protein or a nucleotide sequence encoding the like ligand 1 protein in a biological sample of a patient indicates the presence of severe infections.

Furthermore, the present invention relates to a method for the in vitro diagnosis of a severe infection, the method comprising determining in a biological sample a ligand-like 1 protein or a nucleotide sequence encoding a ligand-like 1 protein, wherein an elevated level of expression of the ligand-like 1 protein or an elevated level of the nucleotide sequence encoding the ligand-like 1 protein is indicative for an infection.

Surprisingly, it was found that ligand 1-like has a high level of reliability as a biomarker for severe infections (in particular sepsis). The advantages of the diagnostic biomarkers of the invention are earlier diagnosis of infection, timely treatment and improved disease outcome. Unnecessary costs associated with detecting other biomarkers that exhibit lower sensitivity and selectivity than the sample ligand 1 are also reduced.

Drawings

FIG. 1 Western blot. Isolation of CD14 from blood of healthy donors⁺Monocytes and use 1 × 10⁶Bacteria/m L (Escherichia coli), Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterococcus faecalis, in vitro infection, or stimulation with 100ng/m L lipopolysaccharide (L PS). after two hours, gentamicin was used to kill the bacteria.

Figure 2 shows the results of E L ISA of 12 week old mice injected (i.p.) with L PS (n-16) or NaCl (n-15; control), blood samples were taken twenty-four hours post injection and plasma concentrations were quantified by mouse D LL-1E L ISA (p ≦ 0.0001; mann-whitney U test).

Figure 3 shows E L ISA analysis of the expression levels of (a) D LL-1 or (B) D LL-4 in plasma samples collected from sepsis patients (n ═ 50) immediately after the first confirmation of sepsis symptoms (t0), at 24 hours (t24), at 48 hours (t48) and at 168 hours (t168), and E L ISA results of plasma samples from healthy donors (healthy; n ═ 20) and abdominal post-surgery control patients (48 h post OP ("OPt 2"; n ═ 20). p ≦ 0.0001; mann-whitney U test.

FIG. 4 shows (A) ROC analysis of leukocytes of septic patients at t0 relative to control patients, (B) ROC analysis of CRP levels of septic patients at t0 relative to control patients, C) ROC analysis of D LL-1 levels of septic patients at t0 relative to control patients, D) ROC analysis of D LL-1 levels of septic patients at t0 relative to healthy volunteers, E) ROC analysis of D LL-4 levels of septic patients at t0 relative to control patients, F) ROC analysis of D LL-4 levels of septic patients at t0 relative to healthy volunteers.

Figure 5 shows E L ISA analysis of D LL-1 protein levels in plasma samples of sepsis patients ("sepsis"; group 1: n-30, group 2: n-50, group 3: n-100), control patients after extensive visceral surgery ("post OP"; group 1: n-30, group 2: n-20), and healthy subjects ("healthy"; group 1: n-30, group 2: n-20) · p ≦ 0.0001; mann-whitney U test) in three independent clinical studies (group 1(a), group 2(B), group 3 (C); see example 4 for more details).

Fig. 6 shows E L ISA analysis (a) of D LL-1 protein levels in plasma samples taken from a patient cohort immediately after (n ═ 38) severe trauma, immediately ("initial") after inclusion, 24 hours ("24 h") after inclusion, and 48 hours ("48 h") after inclusion (most recently within 24h after clinical symptoms appeared). the same study (B) was performed on a patient cohort that had undergone heart surgery in extracorporeal circulation (n ═ 25). protein levels are shown preoperatively ("pre-OP"), 4 hours after extracorporeal circulation ("4 h after ECC"), and 24 hours after extracorporeal circulation ("24 h after ECC").

Figure 7 shows the ROC analysis of the D LL-1 protein level in plasma samples (sepsis patients: n-327; control: n-377).

FIG. 8 shows CD14 isolated from healthy donor blood⁺Monocytes stimulated with 100ng/ml L PS or 10⁸Escherichia coli/10⁶Two hours after infection of individual monocytes, the bacteria were killed with gentamicin control cells (-) were not treated the next day cell lysates were prepared for western blot analysis, equal amounts of protein lysates were blotted and probed with antibodies against D LL 1 or actin (loading controls).

The following examples are intended to further illustrate the invention with particular reference to specific embodiments and the accompanying drawings, however, these examples are not intended to limit the disclosure.

Detailed Description

D LL-1 is alias like ligand 1, like protein, H-,1, Drosophila homolog 1, like classical Notch ligand 1, D L, Notch ligand-like 1 three like genes exist in mammals encoding like ligand 1(D L encodes D LL), like ligand 3(D LL encodes D LL) and like ligand 4(D LL encodes D LL), all ligands comprising a conserved cysteine-rich region called DS L (jagged, L ag2) domain, several Epidermal Growth Factor (EGF) like repeats and a transmembrane domain the amino acid sequence of like ligand 1 protein and the nucleotide sequence encoding like ligand 1 protein are known, e.g. the amino acid sequence of D LL is described in the literature "amino acids sequences of America"/"the amino acid sequences of America", WO LL, Journal of the Biotech, homology 3, Saponin Biotech, Voorth technologies, Voorth, Vorons, No. 5, Vorons, Voronoi, Voronage, Vorongeur, Voronge.

The ligand 1-like protein used in the present invention may be a protein encoded by the nucleotide sequence SEQ ID NO. 1 or a nucleotide sequence having at least 80%, preferably 85% or 90% identity to SEQ ID NO. 1.

Furthermore, the ligand 1-like protein may be a protein having at least 90% identity, in particular 95% identity, to the amino acid sequence SEQ ID NO 2 or SEQ ID NO 3.

The term ligand 1 protein as used herein for the purposes of the present invention also includes the naturally occurring cleavage product of D LL. the naturally occurring cleavage product according to the present invention includes extracellular cleavage products, transmembrane cleavage products and intracellular cleavage products. in a preferred embodiment, the naturally occurring cleavage product is an extracellular cleavage product. thus, the term ligand 1 protein also includes polypeptides consisting essentially of N-or C-terminal fragments of the SEQ ID NO:2 protein, which are elevated upon severe infection, in particular sepsis. thus, the term D LL protein includes the post-translationally modified, naturally proteolyzed and processed D LL protein, which also includes the soluble, insoluble D LL protein and the natural isoforms of the D LL protein of SEQ ID NO:2 or SEQ ID NO: 3(D ProtKB-O48 (D2 _ HUMAN). D LL such suitable natural cleavage products of the transmembrane domain of the protein represented by, for example, the amino acids SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: LL, and the intracellular domain of the soluble protein of SEQ ID NO: 466. the protein represents the intracellular domain of the protein of SEQ ID NO: 466. the protein.

The term D LL 1 protein also includes proteins modified by, for example, phosphorylation, methylation, acetylation, and glycosylation.

In the present invention, the level of the D LL 1 protein and/or the level of the D LL 1 nucleotide sequence is determined As used herein, the term nucleotide sequence may refer to DNA, cDNA, RNA or mRNA the nucleotide sequence encoding the D LL 1 protein or D LL 1 protein isoform may also be a splice variant at the RNA level.

According to one embodiment of the present invention, when the nucleotide sequence D LL 1 is used as a biomarker for diagnosing infection or in a method for diagnosing infection in vitro, an increased expression level of D LL 1 indicates severe infection, an exemplary nucleotide sequence of D LL 1 for determining the expression level is SEQ ID NO. 1.

The reference to the nucleotide sequence D LL 1 labelled SEQ ID NO 1 is the DNA sequence of human (Homo sapiens). it is clear, however, that the invention is not limited to humans, but extends to all mammals.

As used herein, the term "elevated" refers to an elevated level compared to a control, a control can be any uninfected biological sample or system, generally, the control and the infected biological sample or system are of the same species.

Alternatively, for determining the amount of increase in D LL 1 or for diagnosing severe infections, a cut-off value is determined and taken into account when testing patient samples according to the invention, which is also beneficial for diagnosing sepsis.

The expression level of D LL 1 can be determined in any biological sample the term "biological sample" as used herein includes the entire organism or any portion of the organism.

In one embodiment of the invention, the expression level of D LL 1 is determined from a single cell or cell culture.

In another embodiment, the expression level of D LL 1 is determined from tissue, preferably the expression level of D LL 1 is determined from a blood sample, as used herein, the term "blood" includes whole blood, plasma, and serum, preferably the expression level of D LL 1 is determined from a plasma sample.

In a preferred embodiment, the expression level of D LL 1 is determined and determined from a plasma sample taken from a patient As used herein, the term "patient" includes humans and non-human mammals at risk of severe infection or sepsis.

Protein expression levels may also be determined and determined using immunoblot assays (e.g., western blot assays), mass spectrometry, E L ISpot, or flow cytometry and immunohistochemistry techniques.

Expression levels of D LL 1 can be determined using any suitable means of determining nucleotide expression for example, expression can be determined by performing microarray analysis, Polymerase Chain Reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), Northern blot, Southern blot, or Serial Analysis of Gene Expression (SAGE).

Severe infections are medical conditions that are particularly to be avoided, which can lead to life-threatening organ failure caused by a deregulated immune response to the infection. Examples of severe infections are sepsis, pneumonia and meningitis.